A newly published protocol describes ACO-SWITCH, a phase 4, single-arm study designed to monitor serum transthyretin changes in 50 adults switching from tafamidis to acoramidis. The study is intended to document biochemical response after a change in therapy rather than comparing outcomes versus continued tafamidis. Because transthyretin lowering is the core pharmacodynamic target in ATTR-cardiomyopathy, the protocol aims to quantify the extent and durability of TTR suppression after the transition. That can inform real-world treatment decisions and may help clinicians manage therapy switching when patients move between approved options. For companies and clinical teams, the protocol adds to the evidence infrastructure around ATTR regimen changes, where randomized head-to-head data can be limited.